Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10244MR)

This product GTTS-WQ10244MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10244MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11616MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ15734MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ13052MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ14327MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ12223MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ12319MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ12891MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ15132MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW